How does dasatinib perform in the treatment of chronic myelogenous leukemia?

Dasatinib has excellent performance in the treatment of chronic myelogenous leukemia (CML) and is one of the commonly used targeted therapeutic drugs in clinical practice.

Dasatinib, as a second-generation tyrosine kinase inhibitor, has a powerful inhibitory effect. It can bind to the activated and non-activated conformations of BCR-ABL, and its inhibitory effect on BCR-ABL is hundreds of times stronger than the first-generation inhibitor imatinib. This dual inhibitory effect not only enables dasatinib to achieve higher hematological and cytogenetic response rates in the treatment of patients with first-episode CML, but also makes it equally effective in patients who are resistant or intolerant to imatinib.

Dasatinib is suitable for all stages of chronic myelogenous leukemia, including chronic phase, accelerated phase and blast phase. For patients with initial disease, dasatinib can be used as a first-line treatment; for patients who fail imatinib treatment, dasatinib provides an effective alternative treatment. In addition, dasatinib can also pass through the blood-brain barrier and kill leukemia cells in the central nervous system, which is of great significance for the prevention and treatment of central nervous system infiltration.

Although dasatinib may cause some adverse reactions during treatment, such as bone marrow suppression, pleural effusion, pulmonary infection, etc., overall, it is safe and well tolerated. Most adverse reactions are mild to moderate and can be alleviated by adjusting the dose or taking corresponding treatment measures. In addition, dasatinib even showed a lower incidence of adverse reactions in some aspects compared with imatinib.

Effective treatment with dasatinib not only helps control disease progression, but also improves patients’ quality of life. By inhibiting the proliferation of leukemia cells and inducing their apoptosis, dasatinib can alleviate patients' clinical symptoms, such as anemia, bleeding, infection, etc. At the same time, due to the targeted therapeutic effect of dasatinib, it kills leukemia cells while causing less damage to normal cells, which helps reduce side effects during treatment and improve patient tolerance.